Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · head-neck@1

SRR6079988

—

85532855-4799-5243-b289-67a3c7d8b125

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—
sex
male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.510
  • G2M_CHECKPOINT+0.450
  • MYC_TARGETS_V1+0.430
  • MYC_TARGETS_V2+0.250
  • SPERMATOGENESIS+0.220
  • MITOTIC_SPINDLE+0.180
  • DNA_REPAIR+0.160
  • UV_RESPONSE_DN+0.140
  • OXIDATIVE_PHOSPHORYLATION+0.120
  • PANCREAS_BETA_CELLS+0.120

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.660
  • INTERFERON_GAMMA_RESPONSE-0.550
  • IL6_JAK_STAT3_SIGNALING-0.490
  • ALLOGRAFT_REJECTION-0.470
  • INFLAMMATORY_RESPONSE-0.410
  • TNFA_SIGNALING_VIA_NFKB-0.380
  • COMPLEMENT-0.300
  • XENOBIOTIC_METABOLISM-0.300
  • CHOLESTEROL_HOMEOSTASIS-0.290
  • HEDGEHOG_SIGNALING-0.270

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MBCProject_6109_T1B_RNA
breast-umap@18
—B0.901
2AUR-AD9E-TTM1-A-1-1-R-A542-39
breast-umap@18
—B0.882
3MBCProject_6109_T1C_RNA
breast-umap@18
—B0.881
4SRR8518449
breast-umap@18
—E0.875
5sclc272882_S79.txt
lung-landscapes@6
—cohortSC0.861
6BS_81SP2HX4
brain-umap@2
medulloblastoma—0.860
7MBCProject_6127_T1_RNA
breast-umap@18
—B0.853
8TCGA-50-5931-01A-11R-1755-07
lung-landscapes@6
—cohortMD10.851
9C3N-03076
lung-landscapes@6
—cohortMD10.851
10SRR15069603
head-neck@1
——0.851

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 19 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.510Inavolisib— uncovered
G2M_CHECKPOINT0.450Inavolisib— uncovered
MYC_TARGETS_V10.430Inavolisib— uncovered
MYC_TARGETS_V20.250Idelalisib— uncovered
SPERMATOGENESIS0.220Inavolisib— uncovered
MITOTIC_SPINDLE0.180Inavolisib— uncovered
DNA_REPAIR0.160Idelalisib— uncovered
UV_RESPONSE_DN0.140Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.120Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.120Cobimetinib— uncovered
APICAL_JUNCTION0.110Inavolisib— uncovered
PROTEIN_SECRETION0.110Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.090Inavolisib— uncovered
TGF_BETA_SIGNALING0.090Inavolisib— uncovered
GLYCOLYSIS0.080Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.060Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.040Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.010Inavolisib— uncovered
MTORC1_SIGNALING0.010Inavolisib— uncovered